New Clinical Trial Data: Vivo Technology Shows Promise in Treating Pediatric Sleep Apnea
A recent multi-center clinical trial published in the European Journal of Pediatrics demonstrated the safety and efficacy of Vivos...
eClinical Tech News
Entera Bio’s EB613 Shows Promising Effects on Bone Health in Post-Menopausal Women
Entera Bio announced that data from its Phase 2 study of EB613, an oral PTH(1-34) treatment for osteoporosis, was...
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311
Invivyd announced positive Phase 1/2 clinical trial data for VYD2311, its next-generation monoclonal antibody designed to prevent and treat...
Altimmune Announces Positive Topline Results for Pemvidutide
Altimmune, Inc. announced positive topline results from its Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH)....
CRISPR Therapeutics Reports Positive Phase 1 Data for CTX310™
CRISPR Therapeutics announced updates on its in vivo cardiovascular disease programs, including new Phase 1 data for CTX310 targeting...
Pliant Therapeutics Announces Positive Update on Phase 2a Beacon-IPF Study
Pliant Therapeutics has halted the development of bexotegrast for idiopathic pulmonary fibrosis (IPF) after a Phase 2b/3 trial, BEACON-IPF,...
HCW Biologics: IND-Enabling T-Cell Engager Updates & Preclinical Success
HCW Biologics has developed second-generation, multi-specific T-cell engagers targeting solid tumors, particularly pancreatic cancer, using its proprietary TRBC platform....
Tango Tx Doses First Patient in TNG462 Phase 1/2 Trial
Tango Therapeutics has initiated a Phase 1/2 trial evaluating TNG462, a PRMT5 inhibitor, in combination with Revolution Medicines’ RAS...
GlucoTrack’s Continuous Glucose Monitor Shows Positive Results in Human Study
Glucotrack, Inc. announced positive results from its first-in-human clinical study of its implantable continuous blood glucose monitor (CBGM). The...
Amneal’s Biosimilar Candidate Positive Topline Results
Amneal Pharmaceuticals announced positive topline results from a Phase 3 trial of ADL-018, a biosimilar to XOLAIR® (omalizumab), developed...